Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Recurrence 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Spinocerebellar Degenerations 1Solid Tumor 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Pancreatic Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Hodgkin Disease 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 10Rituximab 9polatuzumab vedotin 6Prednisone 6Doxorubicin 6Vincristine 5zanubrutinib 4glofitamab 4Prednisolone 4Lenalidomide 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Lisaftoclax 3tafasitamab 2obinutuzumab 2fludarabine 2Radiotherapy 2R-CHOP protocol 2Observation 2venetoclax 1sintilimab 1resiniferatoxin 1penpulimab 1pegfilgrastim 1orelabrutinib 1loncastuximab tesirine 1duvelisib 1acalabrutinib 1Vancomycin 1Therapeutics 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Large B-Cell, Diffuse × sintilimab × Clear all
NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Not yet recruiting
100 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡